Publication

Article

Oncology & Biotech News
February 2012
Volume 6
Issue 2

Tivantinib Extends Time to Progression in HCC Patients

Author(s):

Treatment with tivantinib produced a 56% improvement in time-to-progression in patients with hepatocellular carcinoma.

liver

Treatment with tivantinib produced a 56% improvement in time-to-progression (TTP) in patients with hepatocellular carcinoma (HCC) (hazard ratio = 0.64; P = .04), according to information released by ArQule, which is developing tivantinib.

Tivantinib is an experimental selective inhibitor of c-Met, a receptor tyrosine kinase, which is given orally. In some cancer cells, c-Met plays multiple roles, including cell growth, survival, angiogenesis, invasion, and metastasis.

The 107 patients in this randomized, controlled phase II trial had unresectable HCC and had experienced disease progression after first-line therapy or were unable to tolerate such therapy. HCC is the most common primary cancer of the liver.

At the start of the study, patients were randomized to receive 360 mg BID of tivantinib or placebo. Due to the rate of neutropenia, the tivantinib dose was reduced to 240 mg BID for all patients in the treatment arm.

TTP was defined as the time from patient randomization until objective tumor progression using RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria evaluated by radiologists.

Adverse events were similar in the treatment and placebo arms, except for a higher incidence of fatigue and hematologic events, including neutropenia and anemia, in tivantinib-treated patients. The incidence of hematologic events declined after the dose reduction.

Related Videos
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD